TrialCancer2016

Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496).

Stefan K Barta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.